Across TCGA pan-cancer cohorts, MTCYBP42 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated MTCYBP42 data layer.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTCYBP42 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCYBP42 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.
HNSC, THCA, and LIHC are the cancer types where MTCYBP42 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.